{
    "organizations": [],
    "uuid": "9ebc092f8ae1a597f8d4f3cbf59e143848e0ed82",
    "author": "Jonathan D. Rockoff",
    "url": "https://www.wsj.com/articles/pfizer-plans-5-billion-boost-in-u-s-manufacturing-from-tax-law-changes-1517319342",
    "ord_in_thread": 0,
    "title": "Pfizer Plans $5 Billion Boost in U.S. Manufacturing From Tax Law Changes",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Pfizer Inc. offered a rosy outlook for the year, outlining the benefits from the new U.S. tax law and casting the Amazon.com Inc.-led partnership to lower health-care costs as positive for the drug industry.\nNew York-based Pfizer reported for the fourth quarter a profit of $12.27 billion, or $2.02 a share, up from $775 million, or 13 cents a share, a year earlier. The big gain came largely from a $10.7 billion benefit from the revaluation of deferred tax liabilities.\n... ",
    "published": "2018-01-30T22:00:00.000+02:00",
    "crawled": "2018-01-31T01:48:20.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pfizer",
        "offered",
        "rosy",
        "outlook",
        "year",
        "outlining",
        "benefit",
        "new",
        "tax",
        "law",
        "casting",
        "partnership",
        "lower",
        "cost",
        "positive",
        "drug",
        "industry",
        "new",
        "pfizer",
        "reported",
        "fourth",
        "quarter",
        "profit",
        "billion",
        "share",
        "million",
        "cent",
        "share",
        "year",
        "earlier",
        "big",
        "gain",
        "came",
        "largely",
        "billion",
        "benefit",
        "revaluation",
        "deferred",
        "tax",
        "liability"
    ]
}